<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>دانشگاه اصفهان</PublisherName>
				<JournalTitle>زیست شناسی میکروبی</JournalTitle>
				<Issn>3060-7647</Issn>
				<Volume>14</Volume>
				<Issue>55</Issue>
				<PubDate PubStatus="epublish">
					<Year>2025</Year>
					<Month>11</Month>
					<Day>22</Day>
				</PubDate>
			</Journal>
<ArticleTitle>DinI could be a suitable option in drug targeting strategies to reduce SOS mutagenesis</ArticleTitle>
<VernacularTitle>DinI could be a suitable option in drug targeting strategies to reduce SOS mutagenesis</VernacularTitle>
			<FirstPage>1</FirstPage>
			<LastPage>6</LastPage>
			<ELocationID EIdType="pii">29071</ELocationID>
			
<ELocationID EIdType="doi">10.22108/bjm.2024.142477.1610</ELocationID>
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Razieh</FirstName>
					<LastName>Pourahmad Jaktaji</LastName>
<Affiliation>Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Sare</FirstName>
					<LastName>Mohammadi</LastName>
<Affiliation>Department  of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2024</Year>
					<Month>08</Month>
					<Day>15</Day>
				</PubDate>
			</History>
		<Abstract>Ciprofloxacin induces the SOS response. Induction of the SOS response confers resistance to ciprofloxacin through activation of DNA polymerase V. However, mutations in &lt;em&gt;lexA&lt;/em&gt;, &lt;em&gt;umuDC&lt;/em&gt; and especially &lt;em&gt;recA&lt;/em&gt; prevent the evolution of resistance to ciprofloxacin. Alternatively, mutations in SOS proteins that regulate RecA activity, such as DinI, can reduce SOS mutagenesis. The aim of this study was to investigate the effect of DinI&lt;em&gt; &lt;/em&gt;inactivation on the frequency of mutagenesis and expression of the &lt;em&gt;umuD&lt;/em&gt; and &lt;em&gt;rdgC&lt;/em&gt; genes after treatment with ciprofloxacin and to examine the promoter region and the 3′ end of the &lt;em&gt;recA&lt;/em&gt; gene for possible changes in &lt;em&gt;dinI&lt;/em&gt; (SM1 and SM2) mutants. Ciprofloxacin-resistant clones (SM1 and SM2) derived from the JW10481 (&lt;em&gt;dinI&lt;sup&gt;- &lt;/sup&gt;&lt;/em&gt;) strain were used in this study. Mutagenesis analysis and real-time PCR were used to measure the frequency of mutant cells and the expression of &lt;em&gt;umuD&lt;/em&gt; and &lt;em&gt;rdgC&lt;/em&gt; genes in mutants, respectively. The promoter region and &lt;em&gt;recA&lt;/em&gt; gene sequence were examined by PCR amplification and DNA sequencing in &lt;em&gt;dinI&lt;sup&gt;-&lt;/sup&gt;&lt;/em&gt; clones. SOS mutagenesis was significantly reduced (P&lt;0.05) in SM1 and SM2 clones&lt;strong&gt;.&lt;/strong&gt; These clones (&lt;em&gt;dinI&lt;sup&gt;-&lt;/sup&gt;&lt;/em&gt;) did not show overexpression of the &lt;em&gt;umuD&lt;/em&gt; gene. &lt;em&gt;rdgC&lt;/em&gt; gene was overexpressed in SM2, but not in the M2 mutant with intact &lt;em&gt;dinI&lt;/em&gt; gene. Furthermore, DNA sequencing did not reveal any change in the &lt;em&gt;recA&lt;/em&gt; gene sequence. The low frequency of mutagenesis&lt;strong&gt; &lt;/strong&gt;and &lt;em&gt;umuD&lt;/em&gt; expression in clones lacking DinI protein activity demonstrated the importance of this protein in SOS mutagenesis. In conclusion, DinI may be a suitable option in drug targeting strategies to enhance the efficacy of ciprofloxacin in combination therapy against a variety of infections caused by &lt;em&gt;Escherichia coli&lt;/em&gt; and other Gram-negative bacteria with homologues of this protein.</Abstract>
			<OtherAbstract Language="FA">Ciprofloxacin induces the SOS response. Induction of the SOS response confers resistance to ciprofloxacin through activation of DNA polymerase V. However, mutations in &lt;em&gt;lexA&lt;/em&gt;, &lt;em&gt;umuDC&lt;/em&gt; and especially &lt;em&gt;recA&lt;/em&gt; prevent the evolution of resistance to ciprofloxacin. Alternatively, mutations in SOS proteins that regulate RecA activity, such as DinI, can reduce SOS mutagenesis. The aim of this study was to investigate the effect of DinI&lt;em&gt; &lt;/em&gt;inactivation on the frequency of mutagenesis and expression of the &lt;em&gt;umuD&lt;/em&gt; and &lt;em&gt;rdgC&lt;/em&gt; genes after treatment with ciprofloxacin and to examine the promoter region and the 3′ end of the &lt;em&gt;recA&lt;/em&gt; gene for possible changes in &lt;em&gt;dinI&lt;/em&gt; (SM1 and SM2) mutants. Ciprofloxacin-resistant clones (SM1 and SM2) derived from the JW10481 (&lt;em&gt;dinI&lt;sup&gt;- &lt;/sup&gt;&lt;/em&gt;) strain were used in this study. Mutagenesis analysis and real-time PCR were used to measure the frequency of mutant cells and the expression of &lt;em&gt;umuD&lt;/em&gt; and &lt;em&gt;rdgC&lt;/em&gt; genes in mutants, respectively. The promoter region and &lt;em&gt;recA&lt;/em&gt; gene sequence were examined by PCR amplification and DNA sequencing in &lt;em&gt;dinI&lt;sup&gt;-&lt;/sup&gt;&lt;/em&gt; clones. SOS mutagenesis was significantly reduced (P&lt;0.05) in SM1 and SM2 clones&lt;strong&gt;.&lt;/strong&gt; These clones (&lt;em&gt;dinI&lt;sup&gt;-&lt;/sup&gt;&lt;/em&gt;) did not show overexpression of the &lt;em&gt;umuD&lt;/em&gt; gene. &lt;em&gt;rdgC&lt;/em&gt; gene was overexpressed in SM2, but not in the M2 mutant with intact &lt;em&gt;dinI&lt;/em&gt; gene. Furthermore, DNA sequencing did not reveal any change in the &lt;em&gt;recA&lt;/em&gt; gene sequence. The low frequency of mutagenesis&lt;strong&gt; &lt;/strong&gt;and &lt;em&gt;umuD&lt;/em&gt; expression in clones lacking DinI protein activity demonstrated the importance of this protein in SOS mutagenesis. In conclusion, DinI may be a suitable option in drug targeting strategies to enhance the efficacy of ciprofloxacin in combination therapy against a variety of infections caused by &lt;em&gt;Escherichia coli&lt;/em&gt; and other Gram-negative bacteria with homologues of this protein.</OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Ciprofloxacin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">DinI</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Escherichia coli</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mutagenesis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">SOS response</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://bjm.ui.ac.ir/article_29071_70d812330811b4a612eb9efb5f840430.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
